Finnish drugmaker Orion Corporation has announced that it is establishing a new research and development (R&D) center in Cambridge, UK, during 2025 to accelerate its global growth strategy and the development of innovative medicines.
The new center will focus on the development of new biological and large-molecule therapies, with biologics chemistry, manufacturing, and controls (CMC) capabilities and project leadership to support the Orion biologics research projects which are moving towards clinical phase.
Outi Vaarala, executive vice president of innovative medicines and R&D, Orion, said: “Biologics are the fastest growing segment in pharma, representing huge opportunities for new innovative treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze